DDrare: Database of Drug Development for Rare Diseases

40. 高安動脈炎
［臨床試験数：22，薬物数：46（DrugBank：20），標的遺伝子数：22，標的パスウェイ数：111］

Searched query = "Takayasu arteritis", "Aortitis syndrome", "Pulseless disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZA; Acetate; Adalimumab; Anti-thymocyte globulin; CYC; Clofarabine; Cyclophosphamide; Cyclosporine; DCB; Filgrastim; Glucocorticoids; INFLIXIMAB; Infliximab; Leflunomide; Leflunomide 10mg Tab; MMF; MTX; Methotrexate; Methotrexate Tablets; Methylprednisolone; Naltrexone; Naltrexone Hydrochloride; Placebo; Prednisolone; Prednisone; Prednisone Acetate; Prednisone acetate; Prednisone, cyclophosphamide; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Procedure: Computed Tomography; Procedure: Digital substraction angiography (DSA); Procedure: Drug coated balloon (DCB); Procedure: Positron Emission Tomography; Radiation: Fluorine F 18 Clofarabine; Remicade; Remicade (anti tumor necrosis factor inhibitor); RoActemra; RoActemra 20mg/ml; TOCILIZUMAB; Tocilizumab; Tocilizumab (MRA-SC); Tofacitinib; Tofacitinib tablet; Upadacitinib; Yellow Fever Vaccine; Yellow Fever vaccine (17D)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-003753-13-FR (EUCTR)	19/03/2019	13/12/2018	INTOReTAK : INfliximab and TOcilizumab in Refractory/relapsing TAKayasu arteritis	Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis	Patients with refractory or relapsing Takayasu Arteritis desease;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]	Trade Name: RoActemra 20mg/ml Product Name: Tocilizumab INN or Proposed INN: Tocilizumab Other descriptive name: TOCILIZUMAB Product Name: Infliximab INN or Proposed INN: INFLIXIMAB	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 3	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2018-003753-13-FR
(EUCTR)

19/03/2019

13/12/2018

INTOReTAK : INfliximab and TOcilizumab in Refractory/relapsing TAKayasu arteritis

Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis

Patients with refractory or relapsing Takayasu Arteritis desease;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]

Trade Name: RoActemra 20mg/ml
Product Name: Tocilizumab
INN or Proposed INN: Tocilizumab
Other descriptive name: TOCILIZUMAB
Product Name: Infliximab
INN or Proposed INN: INFLIXIMAB

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

France